Trial Profile
A biomarker and phase II study of GW572016 [lapatinib] in recurrent malignant glioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Biomarker; Therapeutic Use
- 23 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.